Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 12, 2011, Pages 1584-1590

  Anekonda, Thimmappa S ^a,b   Quinn, Joseph F ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Autophagy; Beta amyloid; Bioavailability; Tau

Indexed keywords

CALCIUM CHANNEL L TYPE; CASPASE; ISRADIPINE;

ALZHEIMER DISEASE; AUTOPHAGY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEG EDEMA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; AUTOPHAGY; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; HUMANS; ISRADIPINE; TAU PROTEINS;

ANIMALIA;

EID: 80053906347     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.08.013     Document Type: Review

References (106)

1. V1.2 disrupts remote spatial memories in mice. Learn. Mem. 2008, 15:1-5.
2. 2+ channels in the rat hippocampus. J. Comp. Neurol. 2008, 506:569-583.
3. v1.2 calcium channels modulate the spiking pattern of hippocampal pyramidal cells. Life Sci. 2008, 82:41-49.
4. 2+ channel activity and nuclear signaling. Neuron 2007, 55:261-275.
5. 2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci. 2005, 25:9883-9892.
6. Uchida S., Yamada S., Nagai K., Deguchi Y., Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997, 61:2083-2090.
7. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005, 64:113-122.
8. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
9. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 2008, 58:871-883.
10. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 2002, 3:862-872.
11. 2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008, 133:1149-1161.
12. Green K.N., LaFerla F.M. Linking calcium to Abeta and Alzheimer's disease. Neuron 2008, 59:190-194.
13. Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31:454-463.
14. Arispe N., Pollard H.B., Rojas E. beta-Amyloid Ca(2+)-channel hypothesis for neuronal death in Alzheimer disease. Mol. Cell. Biochem. 1994, 140:119-125.
15. Guo Q., Furukawa K., Sopher B.L., Pham D.G., Xie J., Robinson N., Martin G.M., Mattson M.P. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport 1996, 8:379-383.
16. Green K.N., Demuro A., Akbari Y., Hitt B.D., Smith I.F., Parker I., LaFerla F.M. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J. Cell Biol. 2008, 181:1107-1116.
17. Chan S.L., Mayne M., Holden C.P., Geiger J.D., Mattson M.P. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 2000, 275:18195-18200.
18. 2+] in adult Alzheimer's disease mice. J. Neurochem. 2008, 105:262-271.
19. Chakroborty S., Goussakov I., Miller M.B., Stutzmann G.E. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J. Neurosci. 2009, 29:9458-9470.
20. Goussakov I., Miller M.B., Stutzmann G.E. NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. J. Neurosci. 2010, 30:12128-12137.
21. 2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J. Neurochem. 2005, 94:1711-1718.
22. Mattson M.P. Calcium and neurodegeneration. Aging Cell 2007, 6:337-350.
23. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
24. 2+ channels: a possible involvement of free radicals. J. Neurochem. 1997, 68:265-271.
25. V 1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations. J. Alzheimers Dis. 2010, 20:1167-1180.
26. v1.2 calcium channels. J. Neurosci. 2010, 30:8367-8375.
27. Ritz B., Rhodes S.L., Qian L., Schernhammer E., Olsen J.H., Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 2010, 67:600-606.
28. V1.3 neuronal L-type calcium channels: differential targeting and signaling to pCREB. Eur. J. Neurosci. 2006, 23:2297-2310.
29. Anekonda T.S., Quinn J.F., Harris C., Frahler K., Wadsworth T.L., Woltjer R.L. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol. Dis. 2011, 41:62-70.
30. Wang D., Govindaiah G., Liu R., De Arcangelis V., Cox C.L., Xiang Y.K. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 2010, 24:3511-3521.
31. v1.2 via A-kinase anchor protein 150 in neurons. Biochemistry 2007, 46:1635-1646.
32. 2+/calmodulin-dependent protein kinase II in neuronal soma in brain. J. Neurochem. 2005, 94:1438-1447.
33. Scott C.W., Spreen R.C., Herman J.L., Chow F.P., Davison M.D., Young J., Caputo C.B. Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly. J. Biol. Chem. 1993, 268:1166-1173.
34. Honson N.S., Kuret J. Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J. Alzheimers Dis. 2008, 14:417-422.
35. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of Abeta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
36. Nixon R.A. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 2007, 120:4081-4091.
37. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
38. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
39. Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., Mohan P.S., Mercken M., Farmery M.R., Tjernberg L.O., Jiang Y., Duff K., Uchiyama Y., Naslund J., Mathews P.M., Cataldo A.M., Nixon R.A. Macroautophagy-a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 2005, 171:87-98.
40. Nixon R.A. Autophagy in neurodegenerative disease: friend, foe or turncoat?. Trends Neurosci. 2006, 29:528-535.
41. Dolan P.J., Johnson G.V. A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J. Biol. Chem. 2010, 285:21978-21987.
42. Lee J.H., Yu W.H., Kumar A., Lee S., Mohan P.S., Peterhoff C.M., Wolfe D.M., Martinez-Vicente M., Massey A.C., Sovak G., Uchiyama Y., Westaway D., Cuervo A.M., Nixon R.A. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010, 141:1146-1158.
43. Cotman C.W., Poon W.W., Rissman R.A., Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J. Neuropathol. Exp. Neurol. 2005, 64:104-112.
44. Khurana V., Elson-Schwab I., Fulga T.A., Sharp K.A., Loewen C.A., Mulkearns E., Tyynela J., Scherzer C.R., Feany M.B. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet. 2010, 6:e1001026.
45. Cataldo A.M., Nixon R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3861-3865.
46. Hamano T., Gendron T.F., Causevic E., Yen S.H., Lin W.L., Isidoro C., Deture M., Ko L.W. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur. J. Neurosci. 2008, 27:1119-1130.
47. Pickford F., Masliah E., Britschgi M., Lucin K., Narasimhan R., Jaeger P.A., Small S., Spencer B., Rockenstein E., Levine B., Wyss-Coray T. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 2008, 118:2190-2199.
48. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
49. Ma T., Hoeffer C.A., Capetillo-Zarate E., Yu F., Wong H., Lin M.T., Tampellini D., Klann E., Blitzer R.D., Gouras G.K. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e12845.
50. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e9979.
51. Cardoso S.M., Pereira C.F., Moreira P.I., Arduino D.M., Esteves A.R., Oliveira C.R. Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease. Exp. Neurol. 2009, 223:294-298.
52. Braak H., Braak E., Strothjohann M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci. Lett. 1994, 171:1-4.
53. Koson P., Zilka N., Kovac A., Kovacech B., Korenova M., Filipcik P., Novak M. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur. J. Neurosci. 2008, 28:239-246.
54. Zhang Q., Zhang X., Sun A. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models. Acta Neuropathol. 2009, 117:687-697.
55. Siddiqua A., Margittai M. Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease. J. Biol. Chem. 2010, 285:37920-37926.
56. Zilkova M., Zilka N., Kovac A., Kovacech B., Skrabana R., Skrabanova M., Novak M. Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model. J. Alzheimers Dis. 2011, 23:161-169.
57. Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 1996, 2:783-787.
58. Hung K.S., Hwang S.L., Liang C.L., Chen Y.J., Lee T.H., Liu J.K., Howng S.L., Wang C.H. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J. Neuropathol. Exp. Neurol. 2005, 64:15-26.
59. Yang L.S., Ksiezak-Reding H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur. J. Biochem. 1995, 233:9-17.
60. Fujino Y., Wang D.S., Thomas N., Espinoza M., Davies P., Dickson D.W. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J. Neuropathol. Exp. Neurol. 2005, 64:209-214.
61. Quintanilla R.A., Matthews-Roberson T.A., Dolan P.J., Johnson G.V. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J. Biol. Chem. 2009, 284:18754-18766.
62. Zilka N., Filipcik P., Koson P., Fialova L., Skrabana R., Zilkova M., Rolkova G., Kontsekova E., Novak M. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 2006, 580:3582-3588.
63. de Calignon A., Fox L.M., Pitstick R., Carlson G.A., Bacskai B.J., Spires-Jones T.L., Hyman B.T. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204.
64. Zempel H., Thies E., Mandelkow E., Mandelkow E.M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010, 30:11938-11950.
65. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhager W.H., Babarskiene M.R., Babeanu S., Bossini A., Gil-Extremera B., Girerd X., Laks T., Lilov E., Moisseyev V., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
66. Fritze J., Walden J. Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J. Neural. Transm. Suppl. 1995, 46:439-453.
67. Tollefson G.D. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol. Psychiatry 1990, 27:1133-1142.
68. Lopez-Arrieta B.J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database of Systematic Reviews 2002, article no CD000147.
69. Morich F., Bieber F., Lewis J.M., Kaiser L., Cutler N.R., Escobar J.I., Willmer J., Petersen R.C., Reisberg B. Nimodipine in the treatment of probably Alzheimer's disease results of two multicentre trials. Clin. Drug Invest. 1996, 11:185-196.
70. Facchinetti F., Fasolato C., Del Giudice E., Burgo A., Furegato S., Fusco M., Basso E., Seraglia R., D'Arrigo A., Leon A. Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage. Neurobiol. Aging 2006, 27:218-227.
71. Bellew K.M., Pigeon J.G., Stang P.E., Fleischman W., Gardner R.M., Baker W.W. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis. Assoc. Disord. 2004, 18:208-213.
72. Hanyu H., Hirao K., Shimizu S., Sato T., Kiuchi A., Iwamoto T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int. J. Geriatr. Psychiatry 2007, 22:1264-1266.
73. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., Tschanz J.T., Mayer L.S., Welsh-Bohmer K.A., Breitner J.C. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 2006, 63:686-692.
74. Yasar S., Corrada M., Brookmeyer R., Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol. Aging 2005, 26:157-163.
75. Zhang L., Yu J., Pan H., Hu P., Hao Y., Cai W., Zhu H., Yu A.D., Xie X., Ma D., Yuan J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19023-19028.
76. Mai A., Valente S., Meade S., Carafa V., Tardugno M., Nebbioso A., Galmozzi A., Mitro N., De Fabiani E., Altucci L., Kazantsev A. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J. Med. Chem. 2009, 52:5496-5504.
77. Lee I.H., Cao L., Mostoslavsky R., Lombard D.B., Liu J., Bruns N.E., Tsokos M., Alt F.W., Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3374-3379.
78. Bachmeier C., Beaulieu-Abdelahad D., Mullan M., Paris D. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur. J. Pharmacol. 2011, 659:124-129.
79. Paris D., Bachmeier C., Patel N., Quadros A., Volmar C.H., Laporte V., Ganey J., Beaulieu-Abdelahad D., Ait-Ghezala G., Crawford F., Mullan M.J. Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol. Med. 2011, 17:149-162.
80. Simuni T., Borushko E., Avram M.J., Miskevics S., Martel A., Zadikoff C., Videnovic A., Weaver F.M., Williams K., Surmeier D.J. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Dis. 2010, 25:2863-2866.
81. 2+ channels Ca V 1.3 and Ca V 1.2. Bioorg. Med. Chem. 2010, 18:3147-3158.
82. Chan C.S., Gertler T.S., Surmeier D.J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S63-70.
83. V1.3 L-type calcium channels by alternative splicing of a C-terminal regulatory domain. J. Biol. Chem. 2008, 283:20733-20744.
84. Lenhard S.C., Strittmatter R., Price W.J., Chandra S., White R.F., Barone F.C. Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine. Pharmacology 2008, 81:1-10.
85. Campbell C.A., Mackay K.B., Patel S., King P.D., Stretton J.L., Hadingham S.J., Hamilton T.C. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp. Neurol. 1997, 148:45-50.
86. Coon A.L., Wallace D.R., Mactutus C.F., Booze R.M. L-type calcium channels in the hippocampus and cerebellum of Alzheimer's disease brain tissue. Neurobiol. Aging 1999, 20:597-603.
87. Ikeda M., Dewar D., McCulloch J. A correlative study of calcium channel antagonist binding and local neuropathological features in the hippocampus in Alzheimer's disease. Brain Res. 1992, 589:313-319.
88. Barhwal K., Hota S.K., Baitharu I., Prasad D., Singh S.B., Ilavazhagan G. Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: complementary roles of L-type calcium channel and NMDA receptors. Neurobiol. Dis. 2009, 34:230-244.
89. Sica D.A. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J. Clin. Hypertens. (Greenwich) 2005, 7:21-26.
90. Christensen H.R., Antonsen K., Simonsen K., Lindekaer A., Bonde J., Angelo H.R., Kampmann J.P. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?. Pharmacol. Toxicol. 2000, 86:178-182.
91. Sopher B.L., Fukuchi K., Kavanagh T.J., Furlong C.E., Martin G.M. Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. Mol. Chem. Neuropathol. 1996, 29:153-168.
92. Sopher B.L., Fukuchi K., Smith A.C., Leppig K.A., Furlong C.E., Martin G.M. Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res. Mol. Brain Res. 1994, 26:207-217.
93. Copenhaver P.F., Anekonda T.S., Musashe D., Robinson K.M., Swanson T.L., Wadsworth T.L., Kretzschmar D., Woltjer R.L., Quinn J.F. A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. Dis. Mod. Mech. 2011, 4:634-648.
94. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
95. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
96. Sinnegger-Brauns M.J., Huber I.G., Koschak A., Wild C., Obermair G.J., Einzinger U., Hoda J.C., Sartori S.B., Striessnig J. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol. Pharmacol. 2009, 75:407-414.
97. Lacinova L., Klugbauer N., Hofmann F. State- and isoform-dependent interaction of isradipine with the alpha1C L-type calcium channel. Pflugers Arch. 2000, 440:50-60.
98. Diaz J.C., Simakova O., Jacobson K.A., Arispe N., Pollard H.B. Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3348-3353.
99. Cherra S.J., Dagda R.K., Chu C.T. Review: autophagy and neurodegeneration: survival at a cost?. Neuropathol. Appl. Neurobiol. 2010, 36:125-132.
100. Cherra S.J., Kulich S.M., Uechi G., Balasubramani M., Mountzouris J., Day B.W., Chu C.T. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell. Biol. 2010, 190:533-539.
101. 2+ channels. Pflugers Arch. 2010, 460:361-374.
102. Clifton G.D., Blouin R.A., Dilea C., Schran H.F., Hassell A.E., Gonasun L.M., Foster T.S. The pharmacokinetics of oral isradipine in normal volunteers. J. Clin. Pharmacol. 1988, 28:36-42.
103. Sen A.P., Boksa P., Quirion R. Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases. Brain Res. 1993, 611:216-221.
104. Park J.H., Park Y.S., Rhim S.Y., Jhee O.H., Kim S.H., Yang S.C., Lee M.H., Shaw L.M., Kang J.S. Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2009, 877:59-64.
105. Gaggi R., Dall'Olio R., Roncada P., Gianni A.M. Peculiar effects of isradipine and darodipine on the rat brain dopaminergic system. Gen. Pharmacol. 1995, 26:303-308.
106. Sanftner L.M., Gibbons J.A., Gross M.I., Suzuki B.M., Gaeta F.C., Johnson K.W. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica 2009, 39:964-977.